Cure8 news brief
People with IBD may be interested in nonpharmacologic ways to support gut barrier function and reduce inflammation; creatine is being studied for those potential effects.
Adults with IBD (Crohn's disease or ulcerative colitis), clinicians advising patients on supplements, and people exploring adjunct dietary strategies.
The article reports on a review (not a new randomized trial) suggesting creatine helps epithelial cell energy through the creatine kinase/phosphocreatine system, which could help maintain the gut barrier in IBD.
The review authors describe antioxidant and anti‑inflammatory activity and suggest therapeutic potential, but the mindbodygreen piece notes that research is still emerging and more study is needed.
If you’re considering creatine: creatine monohydrate is the most-studied form and common dosing referenced for general use is ~5 g/day; the article recommends discussing supplements with your healthcare provider if you have IBD or other chronic conditions.
The source is a health-news website summarizing a published review. The underlying review synthesizes existing studies rather than reporting new randomized controlled trial results; safety, dosing, and effectiveness for IBD require further rigorous research.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Vitamin D deficiency is common in people with IBD and this study suggests correcting deficiency may help rebalance immune cells and the microbiome—potentially supporting inflammation control alongside standard...
The study suggests that correcting low vitamin D in people with IBD may shift immune responses toward tolerance of gut microbes and associate with lower inflammation—information that could affect monitoring and...
Dietary strategies that reduce inflammation and oxidative stress could complement medical care for people with IBD by potentially lowering biomarkers linked to disease activity.
